GSK plc
GSK plc (GSK) Stock Competitors & Peer Comparison
See (GSK) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GSK | $53.39 | -1.64% | 107B | 14.31 | $3.73 | +3.27% |
| LLY | $985.08 | +0.80% | 929.6B | 42.84 | $23.00 | +0.63% |
| JNJ | $241.52 | -0.21% | 582.1B | 21.88 | $11.04 | +2.14% |
| ABBV | $219.68 | -2.52% | 388.4B | 92.70 | $2.37 | +2.99% |
| NVS | $153.44 | -0.53% | 296.7B | 21.47 | $7.15 | +2.00% |
| AZN | $189.90 | -1.35% | 294.4B | 29.08 | $6.53 | +1.67% |
| MRK | $115.61 | -0.26% | 285.8B | 15.90 | $7.27 | +2.81% |
| AMGN | $366.21 | -0.43% | 197.4B | 25.72 | $14.24 | +2.62% |
| GILD | $144.99 | -0.15% | 180B | 17.79 | $8.15 | +2.20% |
| NVO | $37.96 | -0.16% | 168.7B | 10.61 | $3.58 | +3.23% |
Stock Comparison
GSK vs LLY Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, LLY has a market cap of 929.6B. Regarding current trading prices, GSK is priced at $53.39, while LLY trades at $985.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas LLY's P/E ratio is 42.84. In terms of profitability, GSK's ROE is +0.30%, compared to LLY's ROE of +0.98%. Regarding short-term risk, GSK is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check LLY's competition here
GSK vs JNJ Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, JNJ has a market cap of 582.1B. Regarding current trading prices, GSK is priced at $53.39, while JNJ trades at $241.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas JNJ's P/E ratio is 21.88. In terms of profitability, GSK's ROE is +0.30%, compared to JNJ's ROE of +0.34%. Regarding short-term risk, GSK is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check JNJ's competition here
GSK vs ABBV Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, ABBV has a market cap of 388.4B. Regarding current trading prices, GSK is priced at $53.39, while ABBV trades at $219.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas ABBV's P/E ratio is 92.70. In terms of profitability, GSK's ROE is +0.30%, compared to ABBV's ROE of -3.62%. Regarding short-term risk, GSK is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check ABBV's competition here
GSK vs NVS Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, NVS has a market cap of 296.7B. Regarding current trading prices, GSK is priced at $53.39, while NVS trades at $153.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas NVS's P/E ratio is 21.47. In terms of profitability, GSK's ROE is +0.30%, compared to NVS's ROE of +0.33%. Regarding short-term risk, GSK is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check NVS's competition here
GSK vs AZN Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, AZN has a market cap of 294.4B. Regarding current trading prices, GSK is priced at $53.39, while AZN trades at $189.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas AZN's P/E ratio is 29.08. In terms of profitability, GSK's ROE is +0.30%, compared to AZN's ROE of +0.23%. Regarding short-term risk, GSK is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check AZN's competition here
GSK vs MRK Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, MRK has a market cap of 285.8B. Regarding current trading prices, GSK is priced at $53.39, while MRK trades at $115.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas MRK's P/E ratio is 15.90. In terms of profitability, GSK's ROE is +0.30%, compared to MRK's ROE of +0.36%. Regarding short-term risk, GSK is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check MRK's competition here
GSK vs AMGN Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, AMGN has a market cap of 197.4B. Regarding current trading prices, GSK is priced at $53.39, while AMGN trades at $366.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas AMGN's P/E ratio is 25.72. In terms of profitability, GSK's ROE is +0.30%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, GSK is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check AMGN's competition here
GSK vs GILD Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, GILD has a market cap of 180B. Regarding current trading prices, GSK is priced at $53.39, while GILD trades at $144.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas GILD's P/E ratio is 17.79. In terms of profitability, GSK's ROE is +0.30%, compared to GILD's ROE of +0.41%. Regarding short-term risk, GSK is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check GILD's competition here
GSK vs NVO Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, NVO has a market cap of 168.7B. Regarding current trading prices, GSK is priced at $53.39, while NVO trades at $37.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas NVO's P/E ratio is 10.61. In terms of profitability, GSK's ROE is +0.30%, compared to NVO's ROE of +0.61%. Regarding short-term risk, GSK is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check NVO's competition here
GSK vs PFE Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, PFE has a market cap of 151.2B. Regarding current trading prices, GSK is priced at $53.39, while PFE trades at $26.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas PFE's P/E ratio is 19.41. In terms of profitability, GSK's ROE is +0.30%, compared to PFE's ROE of +0.09%. Regarding short-term risk, GSK is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check PFE's competition here
GSK vs BMY Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, BMY has a market cap of 120.3B. Regarding current trading prices, GSK is priced at $53.39, while BMY trades at $59.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas BMY's P/E ratio is 17.07. In terms of profitability, GSK's ROE is +0.30%, compared to BMY's ROE of +0.39%. Regarding short-term risk, GSK is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check BMY's competition here
GSK vs SNY Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, SNY has a market cap of 105.3B. Regarding current trading prices, GSK is priced at $53.39, while SNY trades at $43.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas SNY's P/E ratio is 18.63. In terms of profitability, GSK's ROE is +0.30%, compared to SNY's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check SNY's competition here
GSK vs BIIB Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, BIIB has a market cap of 26.6B. Regarding current trading prices, GSK is priced at $53.39, while BIIB trades at $181.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas BIIB's P/E ratio is 20.40. In terms of profitability, GSK's ROE is +0.30%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, GSK is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BIIB's competition here
GSK vs HZNP Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GSK is priced at $53.39, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GSK's ROE is +0.30%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check HZNP's competition here
GSK vs GRFS Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, GRFS has a market cap of 6.6B. Regarding current trading prices, GSK is priced at $53.39, while GRFS trades at $7.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas GRFS's P/E ratio is 12.20. In terms of profitability, GSK's ROE is +0.30%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, GSK is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check GRFS's competition here
GSK vs OGN Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, OGN has a market cap of 1.7B. Regarding current trading prices, GSK is priced at $53.39, while OGN trades at $6.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas OGN's P/E ratio is 8.96. In terms of profitability, GSK's ROE is +0.30%, compared to OGN's ROE of +0.26%. Regarding short-term risk, GSK is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check OGN's competition here
GSK vs CELG-RI Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, CELG-RI has a market cap of 268M. Regarding current trading prices, GSK is priced at $53.39, while CELG-RI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.30%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, GSK is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CELG-RI's competition here
GSK vs CTOR Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, CTOR has a market cap of 71.7M. Regarding current trading prices, GSK is priced at $53.39, while CTOR trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas CTOR's P/E ratio is -2.62. In terms of profitability, GSK's ROE is +0.30%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, GSK is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CTOR's competition here
GSK vs SCLX Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, SCLX has a market cap of 70.7M. Regarding current trading prices, GSK is priced at $53.39, while SCLX trades at $8.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas SCLX's P/E ratio is -0.20. In terms of profitability, GSK's ROE is +0.30%, compared to SCLX's ROE of +1.81%. Regarding short-term risk, GSK is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SCLX's competition here
GSK vs MIRA Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, MIRA has a market cap of 50.7M. Regarding current trading prices, GSK is priced at $53.39, while MIRA trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas MIRA's P/E ratio is -0.76. In terms of profitability, GSK's ROE is +0.30%, compared to MIRA's ROE of -9.79%. Regarding short-term risk, GSK is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check MIRA's competition here
GSK vs SRXH Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, SRXH has a market cap of 4.8M. Regarding current trading prices, GSK is priced at $53.39, while SRXH trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas SRXH's P/E ratio is -0.83. In terms of profitability, GSK's ROE is +0.30%, compared to SRXH's ROE of +4.36%. Regarding short-term risk, GSK is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check SRXH's competition here
GSK vs SCLXW Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, SCLXW has a market cap of 1.2M. Regarding current trading prices, GSK is priced at $53.39, while SCLXW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.30%, compared to SCLXW's ROE of +1.81%. Regarding short-term risk, GSK is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for GSK.Check SCLXW's competition here
GSK vs BDSIW Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GSK is priced at $53.39, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas BDSIW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.30%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GSK is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check BDSIW's competition here
GSK vs CRXT Comparison March 2026
GSK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 107B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GSK is priced at $53.39, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 14.31, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GSK's ROE is +0.30%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GSK is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for GSK.Check CRXT's competition here